Related Experiment Video

Updated: Nov 20, 2025

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
08:40

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

6.5K

Doxorubicin for the treatment of hepatocellular carcinoma: GAME OVER!

Boris Guiu1, Eric Assenat2

  • 1Department of Radiology, St-Eloi University Hospital, Montpellier, France.

Annals of Translational Medicine
|January 25, 2021
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

837
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.9K

Related Experiment Videos

Last Updated: Nov 20, 2025

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties
08:40

A Biomimetic Model for Liver Cancer to Study Tumor-Stroma Interactions in a 3D Environment with Tunable Bio-Physical Properties

Published on: August 7, 2020

6.5K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

837
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer Therapies02:49

Cancer Therapies

9.1K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.1K

Articles linked to this work by shared authors, journal, and citation graph.

The landscape of hepatocellular carcinoma recurrence after liver transplantation: a nationwide 14-year study.

JHEP reports : innovation in hepatology·2026

An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn - ALICE (PRODIGE89 - UCGI44 - ALICE).

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026

Spleen stiffness measurement rules out high-risk varices in patients with chronic portal vein thrombosis without cirrhosis.

Journal of hepatology·2026

Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort).

JHEP reports : innovation in hepatology·2026

Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

Liver international : official journal of the International Association for the Study of the Liver·2026

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

The lancet. Gastroenterology & hepatology·2026

Literature review of pediatric Erdheim-Chester disease (ECD) and mixed histiocytosis (Langerhans cell histiocytosis/ECD).

Annals of translational medicine·2026

Erratum: The effect of TLR-4 on the proliferation and differentiation of bone mesenchymal stem cells and its relationship with the Wnt signal transduction pathway during bone nonunion.

Annals of translational medicine·2026

Ferritin as a diagnostic point-of-care marker in iron deficiency anemia: a narrative review and clinical implications.

Annals of translational medicine·2026

The potential of large language models to address patients' preoperative questions before anterior cervical discectomy and fusion surgery.

Annals of translational medicine·2026

Erratum: Krüppel-like factor 5 promotes the progression of oral squamous cell carcinoma via the baculoviral IAP repeat containing 5 gene.

Annals of translational medicine·2026

Tumor microenvironment and signaling pathways in melanoma brain metastasis.

Annals of translational medicine·2026

Is retinal vein occlusion an underrecognized paraneoplastic sentinel of lymphoma? A systematic review and meta-analysis of ocular-haematological interactions.

Acta ophthalmologica·2026

Transcriptome Analysis of Hepatitis C Virus-Infected Hepatoma Cells Following Stringent Removal of Genomic DNA.

Viruses·2026

Double-Edged Sword: HBV-Driven Lipid Metabolism Remodeling in Hepatocarcinogenesis Through Ferroptosis Regulation.

Viruses·2026

SLC27A5 Inhibits HBV Replication Through Regulating FXR/SREBP1C/FASN/ACC1 Pathway in HepAD38 Cells.

Microorganisms·2026

Obinutuzumab and Chemotherapy for Front-Line Treatment of Follicular Lymphoma Grade 3B and Composite Follicular Lymphoma: A Study of the Croatian Cooperative Group for Hematologic Diseases (KroHem).

Pharmaceuticals (Basel, Switzerland)·2026

Onabotulinum Toxin A (BoNTA) in the Treatment of Chronic and High-Frequency Episodic Migraine: A Real-World Study.

Pharmaceuticals (Basel, Switzerland)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us